895 related articles for article (PubMed ID: 26017313)
1. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase.
Cox TR; Rumney RMH; Schoof EM; Perryman L; Høye AM; Agrawal A; Bird D; Latif NA; Forrest H; Evans HR; Huggins ID; Lang G; Linding R; Gartland A; Erler JT
Nature; 2015 Jun; 522(7554):106-110. PubMed ID: 26017313
[TBL] [Abstract][Full Text] [Related]
2. Lysyl oxidase is essential for hypoxia-induced metastasis.
Erler JT; Bennewith KL; Nicolau M; Dornhöfer N; Kong C; Le QT; Chi JT; Jeffrey SS; Giaccia AJ
Nature; 2006 Apr; 440(7088):1222-6. PubMed ID: 16642001
[TBL] [Abstract][Full Text] [Related]
3. P2Y2R activation by nucleotides released from the highly metastatic breast cancer cell MDA-MB-231 contributes to pre-metastatic niche formation by mediating lysyl oxidase secretion, collagen crosslinking, and monocyte recruitment.
Joo YN; Jin H; Eun SY; Park SW; Chang KC; Kim HJ
Oncotarget; 2014 Oct; 5(19):9322-34. PubMed ID: 25238333
[TBL] [Abstract][Full Text] [Related]
4. Lysyl Oxidase Is a Strong Determinant of Tumor Cell Colonization in Bone.
Reynaud C; Ferreras L; Di Mauro P; Kan C; Croset M; Bonnelye E; Pez F; Thomas C; Aimond G; Karnoub AE; Brevet M; Clézardin P
Cancer Res; 2017 Jan; 77(2):268-278. PubMed ID: 27742687
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia/reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration.
Postovit LM; Abbott DE; Payne SL; Wheaton WW; Margaryan NV; Sullivan R; Jansen MK; Csiszar K; Hendrix MJ; Kirschmann DA
J Cell Biochem; 2008 Apr; 103(5):1369-78. PubMed ID: 17685448
[TBL] [Abstract][Full Text] [Related]
6. Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis.
Cox TR; Gartland A; Erler JT
Cancer Res; 2016 Jan; 76(2):188-92. PubMed ID: 26732355
[TBL] [Abstract][Full Text] [Related]
7. MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases.
Pivetta E; Scapolan M; Pecolo M; Wassermann B; Abu-Rumeileh I; Balestreri L; Borsatti E; Tripodo C; Colombatti A; Spessotto P
Breast Cancer Res; 2011 Oct; 13(5):R105. PubMed ID: 22032644
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche.
Erler JT; Bennewith KL; Cox TR; Lang G; Bird D; Koong A; Le QT; Giaccia AJ
Cancer Cell; 2009 Jan; 15(1):35-44. PubMed ID: 19111879
[TBL] [Abstract][Full Text] [Related]
9. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
10. Lysyl oxidase mediates hypoxic control of metastasis.
Erler JT; Giaccia AJ
Cancer Res; 2006 Nov; 66(21):10238-41. PubMed ID: 17079439
[TBL] [Abstract][Full Text] [Related]
11. Established Models and New Paradigms for Hypoxia-Driven Cancer-Associated Bone Disease.
Cox TR; Erler JT; Rumney RMH
Calcif Tissue Int; 2018 Feb; 102(2):163-173. PubMed ID: 29098360
[TBL] [Abstract][Full Text] [Related]
12. GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells.
Chu IM; Michalowski AM; Hoenerhoff M; Szauter KM; Luger D; Sato M; Flanders K; Oshima A; Csiszar K; Green JE
Oncogene; 2012 Apr; 31(16):2017-27. PubMed ID: 21892208
[TBL] [Abstract][Full Text] [Related]
13. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.
Guise TA; Mohammad KS; Clines G; Stebbins EG; Wong DH; Higgins LS; Vessella R; Corey E; Padalecki S; Suva L; Chirgwin JM
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6213s-6216s. PubMed ID: 17062703
[TBL] [Abstract][Full Text] [Related]
14. What Is Breast in the Bone?
Shemanko CS; Cong Y; Forsyth A
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27782069
[TBL] [Abstract][Full Text] [Related]
15. Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway.
Chen LC; Tu SH; Huang CS; Chen CS; Ho CT; Lin HW; Lee CH; Chang HW; Chang CH; Wu CH; Lee WS; Ho YS
Breast Cancer Res Treat; 2012 Aug; 134(3):989-1004. PubMed ID: 22434522
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis.
Nakajima K; Kho DH; Yanagawa T; Harazono Y; Hogan V; Chen W; Ali-Fehmi R; Mehra R; Raz A
Cancer Res; 2016 Mar; 76(6):1391-402. PubMed ID: 26837763
[TBL] [Abstract][Full Text] [Related]
17. Notch3 promotes prostate cancer-induced bone lesion development via MMP-3.
Ganguly SS; Hostetter G; Tang L; Frank SB; Saboda K; Mehra R; Wang L; Li X; Keller ET; Miranti CK
Oncogene; 2020 Jan; 39(1):204-218. PubMed ID: 31467432
[TBL] [Abstract][Full Text] [Related]
18. SREBP-2 aggravates breast cancer associated osteolysis by promoting osteoclastogenesis and breast cancer metastasis.
Jie Z; Xie Z; Xu W; Zhao X; Jin G; Sun X; Huang B; Tang P; Wang G; Shen S; Qin A; Fan S
Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):115-125. PubMed ID: 30394316
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer metastasis to the bone: mechanisms of bone loss.
Chen YC; Sosnoski DM; Mastro AM
Breast Cancer Res; 2010; 12(6):215. PubMed ID: 21176175
[TBL] [Abstract][Full Text] [Related]
20. Pdcd4 repression of lysyl oxidase inhibits hypoxia-induced breast cancer cell invasion.
Santhanam AN; Baker AR; Hegamyer G; Kirschmann DA; Colburn NH
Oncogene; 2010 Jul; 29(27):3921-32. PubMed ID: 20498644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
